REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS

This review article dives deep into Alzheimer's Disease (AD), a progressive and incurable brain disorder. It aims to equip readers with a comprehensive understanding of AD by exploring its history, classification, causes, and risk factors. The article explores the emerging field of Artificial Intelligence (AI) and its potential to revolutionize AD management. It examines how AI can impact diagnostics, treatment strategies, and, particularly, the development of targeted therapies. AI-powered imaging tools, such as Deep Learning-based Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) analysis, have achieved over 90% accuracy in early AD detection by identifying subtle brain changes years before clinical symptoms appear. Machine learning models have also enhanced precision medicine by predicting patient responses to therapies with 85–92% accuracy, optimizing treatment regimens based on genetic and biomarker profiles. These novel delivery systems enhance drug efficacy, improve patient compliance, and reduce systemic toxicity, addressing key challenges in AD treatment. Future developments will focus on AI-guided personalized medicine, smart nanocarriers responsive to AD biomarkers, and AI-powered neuroprosthetics for cognitive rehabilitation. Next, it compares established management methods with the latest investigational drug therapies for AD. This analysis sheds light on promising future directions and potential breakthroughs in AD treatment. However, the article emphasizes the importance of patient safety and highlights the rigorous processes of clinical trials, and regulatory hurdles that new AD therapies and delivery systems must overcome. The review concludes by summarizing the key takeaways and identifying the most promising avenues for future research and development in AD treatment. It emphasizes the potential of these cutting-edge approaches to transform AD care and significantly improve patient quality of life.

Authors

Institutions

Publication Details

Journal
International Journal of Applied Pharmaceutics
Published
2025-05-07
DOI
https://doi.org/10.22159/ijap.2025v17i3.53726
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS

V. Balamuralidhara, Akanksha Lahiri, Anand Akhila, S. K. MANOHAR
International Journal of Applied Pharmaceutics
Alzheimer's disease research and treatments
article

REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS

V. Balamuralidhara, Akanksha Lahiri, Anand Akhila, S. K. MANOHAR
article en

Abstract

This review article dives deep into Alzheimer's Disease (AD), a progressive and incurable brain disorder. It aims to equip readers with a comprehensive understanding of AD by exploring its history, classification, causes, and risk factors. The article explores the emerging field of Artificial Intelligence (AI) and its potential to revolutionize AD management. It examines how AI can impact diagnostics, treatment strategies, and, particularly, the development of targeted therapies. AI-powered imaging tools, such as Deep Learning-based Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) analysis, have achieved over 90% accuracy in early AD detection by identifying subtle brain changes years before clinical symptoms appear. Machine learning models have also enhanced precision medicine by predicting patient responses to therapies with 85–92% accuracy, optimizing treatment regimens based on genetic and biomarker profiles. These novel delivery systems enhance drug efficacy, improve patient compliance, and reduce systemic toxicity, addressing key challenges in AD treatment. Future developments will focus on AI-guided personalized medicine, smart nanocarriers responsive to AD biomarkers, and AI-powered neuroprosthetics for cognitive rehabilitation. Next, it compares established management methods with the latest investigational drug therapies for AD. This analysis sheds light on promising future directions and potential breakthroughs in AD treatment. However, the article emphasizes the importance of patient safety and highlights the rigorous processes of clinical trials, and regulatory hurdles that new AD therapies and delivery systems must overcome. The review concludes by summarizing the key takeaways and identifying the most promising avenues for future research and development in AD treatment. It emphasizes the potential of these cutting-edge approaches to transform AD care and significantly improve patient quality of life.

International Journal of Applied Pharmaceutics
JSS Academy of Higher Education and Research (IN)
Openalex Percentile: Top 87%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS — V. Balamuralidhara, Akanksha Lahiri, et al. · International Journal of Applied Pharmaceutics (2025) | TGRS Research Map | TGRS